Catalent continues big push into cell and gene therapies with Belgian facility buyout

Catalent announced on Octobre 29th that it had signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium. The transaction is expected to close in November 2020. The Bone Therapeutics subsidiary and its facility, which is next to Catalent’s existing cell therapy site, will allow Catalent to expand its industry-leading cell therapy capabilities and advanced clinical and commercial supply, and create an integrated European center of excellence in cell therapy. Catalent is continuing work on its dedicated 60,000 square-foot (5,574 square-meter) commercial-scale production and fill-finish facility in Gosselies, which is scheduled to be completed by the end of 2021.

For further information, see Catalent (https://www.catalent.com/catalent-news/catalent-to-acquire-cell-therapy-manufacturing-facility-from-bone-therapeutics/)

Leave a Reply

Your email address will not be published. Required fields are marked *